NCT02337946 - Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma | Biotech Hunter

Enrollment

164

Participants

Timeline

Start Date

October 16, 2014

Primary Completion Date

March 31, 2017

Study Completion Date

August 31, 2017

Conditions

Colorectal Carcinoma

Interventions

DRUG

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion

DRUG

oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

Trial Locations (49)

Unknown

Nagakute

Nagoya

Okazaki

Toyoaki

Yachiyo

Kitakyushu

Tagawa

Aizu-Wakamatsu

Kakamigahara

Tajimi

Hakodate

Kushiro

Amagasaki

Kakogawa

Kobe

Nishinomiya

Kahoku

Kanazawa

Morioka

Kida-gun

Marugame

Takamatsu

Kawasaki

Yokohama

Nangoku

Sendai

Matsumoto

Suwa

Sasebo

Higashiosaka

Hirakata

Izumi

Izumisano

Sakai

Tondabayashi

Hidaka

Izumo

Fujioka

Shimonoseki

Akita

Fukui

Fukuoka

Gifu

Hiroshima

Kyoto

Nagasaki

Okinawa

Osaka

Saga